Drug Development

Currently, the average cost of developing a single drug has reached $2 billion, with a development timeline of about 10 years. This substantial investment and lengthy process drive up drug prices and heighten the barrier to entry into the pharmaceutical industry.

By integrating biochips like AxoMini, we can now screen drugs more effectively, offering a more effective approach than traditional methods. Utilizing simulators, the efficacy of these drugs can be measured with greater accuracy. This technology significantly boosts the success rates of drugs in clinical trials, leading to reduced R&D costs and ultimately decreasing the overall price of drugs in the market.

By integrating neurons with simulators, we've opened a completely new avenue in drug screening.

Our approach involves developing a simulator in which the entities within are controlled by neurons themselves. This setup permits multiple neural cultures, each in their own biochips, to interact within the virtual environment. By modeling symptoms or disease-specific behaviors onto these entities, we can physically test drugs on the neurons to observe their effectiveness in altering these simulated symptoms.

This approach is poised to enhance the success rates of drugs in clinical trials. By accurately correlating symptoms and behaviors to specific diseases within the simulator, we can identify underperforming drugs and screen them out before entering costly clinical trials.

This method ensures that only the most promising drugs proceed to trial, optimizing both time and resources.

To discover more about our cutting-edge screening platforms or to integrate them into your operations, we encourage you to contact us.